1
|
Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, LeBlanc K, Brune M, Maeurer M, Ljungman P. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. Transpl Infect Dis 2015; 17:371-9. [DOI: 10.1111/tid.12382] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/04/2015] [Accepted: 02/28/2015] [Indexed: 11/30/2022]
Affiliation(s)
- A. Ambati
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
- Department of Medicine; Karolinska Institutet; Huddinge Sweden
| | | | - I. Magalhaes
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
- Center for Allogeneic Stem Cell Transplantation; Karolinska University Hospital; Stockholm Sweden
| | - T. Poiret
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
| | - R. Bodenstein
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
| | - K. LeBlanc
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
- Department of Hematology; Karolinska University Hospital; Stockholm Sweden
| | - M. Brune
- Sahlgrens University Hospital; Goteborg Sweden
| | - M. Maeurer
- Department of Laboratory Medicine; Karolinska Institutet; Huddinge Sweden
- Center for Allogeneic Stem Cell Transplantation; Karolinska University Hospital; Stockholm Sweden
| | - P. Ljungman
- Department of Medicine; Karolinska Institutet; Huddinge Sweden
- Department of Hematology; Karolinska University Hospital; Stockholm Sweden
| |
Collapse
|
2
|
Jamali A, Holtrop M, de Haan A, Hashemi H, Shenagari M, Memarnejadian A, Roohvand F, Sabahi F, Kheiri MT, Huckriede A. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol Lett 2012; 148:77-82. [DOI: 10.1016/j.imlet.2012.08.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 07/16/2012] [Accepted: 08/29/2012] [Indexed: 10/27/2022]
|
3
|
Singh R, Verma PC, Singh S. Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease. Trop Anim Health Prod 2009; 42:465-71. [PMID: 19728133 DOI: 10.1007/s11250-009-9444-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Accepted: 08/14/2009] [Indexed: 11/28/2022]
Abstract
Virosome based vaccines against Newcastle disease (ND) were prepared and evaluated for their immunogenicity and protective efficacy in chickens. Envelop of Newcastle disease virus (NDV) was solubilised with Triton X-100 to yield virosomes which were later on encapsulated in poly-lactide-co-glycolide (PLG) microspheres. The birds were immunized intranasally with virosomes or PLG microspheres encapsulated virosomes, and efficacy of these preparations was compared with commercial LaSota vaccine. The preparations protected the chickens against virulent virus challenge infection, however the microencapsulated virosome vaccine gave slightly lesser degree of protection than non encapsulated counterpart. The humoral and cell mediated immune response generated as well as the protection afforded by virosome preparations were found to be comparable with LaSota vaccine. The results substantiate the potential of virosome based vaccines to provide high level of immunity and protection against Newcastle disease.
Collapse
Affiliation(s)
- Rajinder Singh
- Division of Biological Products, Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| | | | | |
Collapse
|
4
|
Zhang W, Li W, Li Y, Li H, Wang B, Wang F, Zhu Y, Jiang Z, Zhong L, Li M. Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes. J Med Microbiol 2009; 58:845-854. [PMID: 19498203 DOI: 10.1099/jmm.0.006825-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The high variability of influenza virus causes difficulties in the control and prevention of influenza, thus seeking a promising approach for dealing with these problems is a hot topic. Haemagglutinin (HA) and neuraminidase (NA) are major surface antigens of the influenza virus, and provide effective protection against lethal challenges with this virus. We constructed a DNA vaccine (pHA-IRES2-NA) that co-expressed both HA and NA, and compared its protective efficacy and immunogenic ability with that of singly expressed HA or NA, or a mixture of the two singly expressed proteins. Our findings showed that both HA and NA proteins expressed by pHA-IRES2-NA could be detected in vivo and in vitro. The protection of DNA vaccines was evaluated by serum antibody titres, residual lung virus titres and survival rates of the mice. In the murine model, immunization of pHA-IRES2-NA generated significant anti-HA and anti-NA antibody, increased the percentage of CD8(+) cells and gamma interferon-producing CD8(+) cells and the ratio of Th1/Th2 (T helper) cells, which was comparable to the effects of immunization with HA or NA DNA alone or with a mixture of HA and NA DNA. All the mice inoculated by pHA-IRES2-NA resisted the lethal challenge by homologous influenza virus and survived with low lung virus titre. In addition, previous studies reported that co-expression allowed higher-frequency transduction compared to co-transduction of separated vector systems encoding different genes. The novel HA and NA co-expression DNA vaccine is a successful alternative to using a mixture of purified HA and NA proteins or HA and NA DNA.
Collapse
Affiliation(s)
- Weidong Zhang
- Department of Pathobiology, Basic Medical School of Hebei Medical University, Hebei, PR China.,West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Wanyi Li
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Yan Li
- State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Hong Li
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Baoning Wang
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Fengping Wang
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Yuanjun Zhu
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Zhonghua Jiang
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Li Zhong
- West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| | - Mingyuan Li
- State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan 610041, PR China.,West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China
| |
Collapse
|